Brief Healthcare: MergerTalk: Pfizer/Mylan -Don't Overdose on the Sector, but Mylan Over Teva Pair Trade Is Still On and more | Smartkarma
Mylan-Pfizer off-patent merger boosts Teva - Globes
Teva bid for Mylan sparks worries of rising generic drug prices - The Economic Times
Mylan plays monkey-in-the-middle of hostile takeover battles | Fortune
As Teva claims initial stake, Mylan continues to refuse takeover advances | NASDAQ:TEVA
$40B deal: Teva offers to buy Mylan
Teva Makes $40.1 Billion Takeover Bid For Mylan | Mint
Mylan Rejects Teva's $40 Billion Takeover Offer - The New York Times
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Teva's Latest Deal Looks a Healthier Mouthful -- Heard on the Street - WSJ
Teva says Actavis Closing on Track | CHEManager
Pfizer to spinoff, merge off-patent drugs unit with Mylan | Reuters
Teva, Mylan, Perrigo lose $87b value in 4 years - Globes
Teva may buy more Mylan stock despite antitrust allegations - Global Competition Review
Look out, Teva: Mylan's Copaxone copy has already captured serious share | Fierce Pharma
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
EC nod for Mylan merger with Upjohn; Copaxone patent win
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Mylan says merger with Teva would be bad fit | Reuters
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
DOJ Charges Pharma Execs With Price-Fixing; Teva, Mylan Stocks Fall | Stock News & Stock Market Analysis - IBD
